PURPOSE: Transcatheter aortic valve replacement (TAVR) is suggested to be less invasive and/or equally effective in comparison to conventional aortic valve replacement for high-risk symptomatic aortic stenosis patients. We herein report the initial results of a pivotal clinical trial of TAVR in Japan (the PREVAIL JAPAN). METHODS: Sixty-four aortic stenosis patients (mean age 84.3 ± 6.1 years) not suitable for surgery were enrolled at three centers in Japan, with a primary composite endpoint of the 6-month post-procedure improvements in the aortic valve area and New York Heart Association (NYHA) functional classification. RESULTS: A transfemoral approach was used in 37 patients and a transapical approach was used in 27. The device success rate was 91.9 %. After 30 days and 6 months, the rates of mortality from any cause were 8.1 and 11.3 %, respectively. At 6 months, symptomatic stroke was found in 3.1 % of the patients, and silent infarction in 7.8 %. The aortic valve area and mean pressure gradient were significantly improved over time with both approaches (p < 0.001). At 6 months, the NYHA functional classification based on a conventional physician's assessment was improved in 87.9 % of the patients. CONCLUSIONS: We found results that were equivalent to those in other major TAVR trials, such as an acceptable 30-day survival (91.9 %), suggesting that balloon-expandable TAVR is effective for small Japanese AS patients classified as high-risk or inoperable.
PURPOSE: Transcatheter aortic valve replacement (TAVR) is suggested to be less invasive and/or equally effective in comparison to conventional aortic valve replacement for high-risk symptomatic aortic stenosispatients. We herein report the initial results of a pivotal clinical trial of TAVR in Japan (the PREVAIL JAPAN). METHODS: Sixty-four aortic stenosispatients (mean age 84.3 ± 6.1 years) not suitable for surgery were enrolled at three centers in Japan, with a primary composite endpoint of the 6-month post-procedure improvements in the aortic valve area and New York Heart Association (NYHA) functional classification. RESULTS: A transfemoral approach was used in 37 patients and a transapical approach was used in 27. The device success rate was 91.9 %. After 30 days and 6 months, the rates of mortality from any cause were 8.1 and 11.3 %, respectively. At 6 months, symptomatic stroke was found in 3.1 % of the patients, and silent infarction in 7.8 %. The aortic valve area and mean pressure gradient were significantly improved over time with both approaches (p < 0.001). At 6 months, the NYHA functional classification based on a conventional physician's assessment was improved in 87.9 % of the patients. CONCLUSIONS: We found results that were equivalent to those in other major TAVR trials, such as an acceptable 30-day survival (91.9 %), suggesting that balloon-expandable TAVR is effective for small Japanese AS patients classified as high-risk or inoperable.
Authors: Cary W Akins; D Craig Miller; Marko I Turina; Nicholas T Kouchoukos; Eugene H Blackstone; Gary L Grunkemeier; Johanna J M Takkenberg; Tirone E David; Eric G Butchart; David H Adams; David M Shahian; Siegfried Hagl; John E Mayer; Bruce W Lytle Journal: J Thorac Cardiovasc Surg Date: 2008-04 Impact factor: 5.209
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: F Schwarz; P Baumann; J Manthey; M Hoffmann; G Schuler; H C Mehmel; W Schmitz; W Kübler Journal: Circulation Date: 1982-11 Impact factor: 29.690
Authors: Philipp Kahlert; Stephan C Knipp; Marc Schlamann; Matthias Thielmann; Fadi Al-Rashid; Marcel Weber; Uwe Johansson; Daniel Wendt; Heinz G Jakob; Michael Forsting; Stefan Sack; Raimund Erbel; Holger Eggebrecht Journal: Circulation Date: 2010-02-23 Impact factor: 29.690
Authors: Martyn Thomas; Gerhard Schymik; Thomas Walther; Dominique Himbert; Thierry Lefèvre; Hendrik Treede; Holger Eggebrecht; Paolo Rubino; Iassen Michev; Rüdiger Lange; William N Anderson; Olaf Wendler Journal: Circulation Date: 2010-06-21 Impact factor: 29.690
Authors: Nicholas Chew; Jimmy Kim Fatt Hon; Wei Luen James Yip; Siew Pang Chan; Kian-Keong Poh; William Kok-Fai Kong; Kristine Leok Kheng Teoh; Tiong Cheng Yeo; Huay Cheem Tan; Edgar Lik Wui Tay Journal: Singapore Med J Date: 2016-08-12 Impact factor: 1.858